Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.75
XOMA's Cash-to-Debt is ranked lower than
86% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. XOMA: 0.75 )
Ranked among companies with meaningful Cash-to-Debt only.
XOMA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.22 Max: No Debt
Current: 0.75
Equity-to-Asset -1.39
XOMA's Equity-to-Asset is ranked lower than
97% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XOMA: -1.39 )
Ranked among companies with meaningful Equity-to-Asset only.
XOMA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.65  Med: 0.14 Max: 0.93
Current: -1.39
-1.65
0.93
Piotroski F-Score: 2
Altman Z-Score: -81.91
Beneish M-Score: 3.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -3141.19
XOMA's Operating Margin % is ranked lower than
77% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. XOMA: -3141.19 )
Ranked among companies with meaningful Operating Margin % only.
XOMA' s Operating Margin % Range Over the Past 10 Years
Min: -3141.19  Med: -117.91 Max: 13.17
Current: -3141.19
-3141.19
13.17
Net Margin % -3001.07
XOMA's Net Margin % is ranked lower than
77% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. XOMA: -3001.07 )
Ranked among companies with meaningful Net Margin % only.
XOMA' s Net Margin % Range Over the Past 10 Years
Min: -3001.07  Med: -134.79 Max: 0.56
Current: -3001.07
-3001.07
0.56
ROA % -167.23
XOMA's ROA % is ranked lower than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. XOMA: -167.23 )
Ranked among companies with meaningful ROA % only.
XOMA' s ROA % Range Over the Past 10 Years
Min: -167.23  Med: -51.27 Max: 0.92
Current: -167.23
-167.23
0.92
ROC (Joel Greenblatt) % -4217.20
XOMA's ROC (Joel Greenblatt) % is ranked lower than
75% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. XOMA: -4217.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XOMA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4217.2  Med: -425.1 Max: 46.51
Current: -4217.2
-4217.2
46.51
3-Year Revenue Growth Rate -51.60
XOMA's 3-Year Revenue Growth Rate is ranked lower than
85% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. XOMA: -51.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XOMA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -73.1  Med: -21.3 Max: 148.1
Current: -51.6
-73.1
148.1
3-Year EBITDA Growth Rate -32.90
XOMA's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. XOMA: -32.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
XOMA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.3  Med: -16.3 Max: 53.6
Current: -32.9
-49.3
53.6
3-Year EPS without NRI Growth Rate -32.30
XOMA's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. XOMA: -32.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
XOMA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.4  Med: -11.5 Max: 35
Current: -32.3
-52.4
35
GuruFocus has detected 4 Warning Signs with XOMA Corp $XOMA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XOMA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

XOMA Guru Trades in

XOMA Guru Trades in

Q3 2016

XOMA Guru Trades in Q3 2016

Jim Simons 193,095 sh (New)
Paul Tudor Jones 30,725 sh (New)
» More
Q4 2016

XOMA Guru Trades in Q4 2016

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:LVCLF, OTCPK:IGXT, NAS:APOP, NAS:GNMX, NAS:ADMA, OTCPK:THCBF, NAS:PBMD, NAS:ITEK, NAS:OVAS, OTCPK:CELZ, NAS:TRIL, OTCPK:FENCF, OTCPK:BLEVF, AMEX:AMPE, NAS:BLPH, OTCPK:ZLDAF, NAS:TTNP, NAS:CFRX, NAS:CUR, OTCPK:CNNRF » details
Traded in other countries:X0M1.Germany,
Headquarter Location:USA
XOMA Corp discovers and develops antibody-based therapeutics. Its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric or active sites.

XOMA Corp was incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. The Company discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites. The compounds are designed to either enhance or diminish the protein's activity as desired. Its lead product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). It is also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins. Its geographic segments include United States, Europe, and Asia Pacific. The Company's competitors include AbbVie Inc., Biovitrum AB, Allergan, Novartis AG, pSivida, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Emergent BioSolutions, Inc. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of any future products.

Top Ranked Articles about XOMA Corp

XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition
XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program
XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting

BERKELEY, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today the presentation of data from its PTH1R Monoclonal Antibodies Program. The poster, which reports data from a pre-clinical study investigating the efficacy of the Company’s anti-PTH1R antagonist monoclonal antibody in reversing hypercalcemia, will be presented at the American Association for Cancer Research annual meeting, April 1-5, 2017, in Washington, DC.
Hypercalcemia is relatively common in patients with cancer, occurring in up to 30 percent of casesi. Hypercalcemia often occurs in patients with both solid tumors and hematologic malignancies due to release of a protein that activates the parathyroid hormone receptor (PTH1R) thereby leading to potentially dangerous calcium levels. Malignancy often is evident clinically by the time it causes hypercalcemia, and those patients often have a poor prognosis. “Our PTH1R program began as an endocrine program, but because of its unique mechanism-of-action we believe it is also potentially beneficial to oncology patients suffering from hypercalcemia,” said Jim Neal, Chief Executive Officer of XOMA. “We seek partners who have a deep commitment to and expertise in drug development. We believe our PTH1R program could join the other antibodies in our extensive licensing portfolio of fully funded programs that are being advanced by partner companies to benefit patients suffering from a wide range of health conditions.” Poster Presentation Details
Abstract Title: Impacting Humoral Hypercalcemia of Malignancy (HHM) and associated PTH1R-mediated morbidities: Characterization of an anti-PTH1R antagonist monoclonal antibody to reverse hypercalcemia Session: Late-Breaking Research (LB-306): Experimental and Molecular Therapeutics 2Date: Wednesday, April 5, 2017, 8:00am to 12:00pm ETLocation: Poster Section 34, Board 14 For additional information, please visit the AACR website: www.aacr.org. About XOMA’s PTH1R Monoclonal Antibodies Program
XOMA has developed several unique functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism. These antibodies have shown promising efficacy in in vivo studies and potentially could address high unmet medical needs, including primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM). HHM is present in many advanced cancers and is caused by high serum calcium due to increased levels of the PTH1R ligand PTH-related peptide (PTHrP).  Since current HHM treatments often fall short and many cancer patients die from ‘metabolic death’, PTH1R antibodies could prove beneficial for the treatment of HHM. About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies.  Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics.  There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com. Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: the potential of XOMA's portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time; positive momentum in 2017; the significant unmet therapeutic need for certain rare medical conditions associated with hyperinsulinism; the continued generation of antibodies by XOMA's proprietary phage display libraries; the potential of IL-2 to provide opportunities to improve patient outcomes; the potential for PTH1R to address high unmet medical needs; XOMA's intent to license X213 and X358; the possibility of the receipt of up to $4 million in additional sales milestones under our agreements with HCRP; and statements that otherwise relate to future periods. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. i Stewart, AF. Hypercalcemia Associated with Cancer. N Engl J Med 2005; 352:373-379.January 27, 2005DOI: 10.1056/NEJMcp042806.
Investor contact:
Luke Heagle
Pure Communications
1 910-726-1372
[email protected]

Media contact:
Colin Sanford
Pure Communications
1 415-946-1094
[email protected]

Read more...
XOMA Announces Four Presentations at the 2017 ENDO Meeting

Oral and Poster Presentations to Highlight Preclinical and Clinical Program Advances for Hypoglycemia and Hypercalcemia

BERKELEY, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that clinical data for its two hypoglycemia drug candidates, X358 and X129, and a third drug candidate for hypercalcemic endocrine and oncology conditions, will be presented at the Endocrine Society’s 99th Annual Meeting (ENDO 2017), taking place from April 1-4, 2017 in Orlando, Florida.
“We look forward to sharing additional efficacy and safety data on X358 and X129 with the clinical endocrinology community at this year’s ENDO meeting. We are also looking forward to discussing the positive progress and development candidate selection for our anti-PTH1R program targeting serious hypercalcemia associated with hyperparathyroidism and certain malignancies,” said Jim Neal, Chief Executive Officer of XOMA. “This continued positive data positions each of these programs well for partnering activities. Once they are successfully partnered, these programs would expand our portfolio of fully funded programs producing future milestones and royalties that contribute to our goal of delivering positive cash flow and profitability.” The Company will deliver one oral presentation and three poster presentations, they include: Oral Presentation
Abstract title: Single Administration of XOMA 358, an Insulin Receptor Attenuator, Improves Post-Meal and Nighttime Hypoglycemia Profiles in Post Gastric Bypass Hypoglycemia (PGBH) Patients Session: OR14: Glucose Metabolism and Post Bariatric Surgery
Date: Monday, April 3, 2017, 12:30 PM - 12:45 PM
Location: OCCC - W224C
Poster Presentations
Abstract title: Activity of XOMA 358, an Inhibitor of Insulin Action Following Short-Term Administration to Congenital Hyperinsulinism Patients Session: MON 001-056 Pediatric Endocrine Case Reports: Diabetes, Thyroid, and Beyond
Poster number: MON 056
Date: Monday, April 3, 2017, 1:00 PM - 3:00 PM
Location: West Hall B (EXPO Hall)
Abstract title: XOMA 129, a Novel Insulin Receptor Negative Modulator, Is Efficacious in Treating Insulin- Induced Hypoglycemia in Minipigs Session: SAT 575-585 Cellular Signaling Pathways and Regulation of Glucose Metabolism
Poster number: SAT 583
Date: Saturday, April 1, 2017, 1:00 PM - 3:00 PM
Location: West Hall B (EXPO Hall)
Abstract title: A Novel Anti-PTH1R Receptor Antagonist Monoclonal Antibody Reverses Hypercalcemia Induced By PTH or PTHrP: A Potential Treatment of Primary Hyperparathyroidism and Humoral Hypercalcemia of Malignancy Session: SAT 338-359 Innovations in Bone Biology
Poster number: SAT 339
Date: Saturday, April 1, 2017, 1:00 PM - 3:00 PM
Location: West Hall B (EXPO Hall)
More information about the ENDO program can be found at: www.endocrine.org/endo-2017/meeting-program About X358
Insulin is the major physiologic hormone for controlling blood glucose levels. Abnormal increases in insulin secretion can lead to profound hypoglycemia (low blood sugar), a state that can result in significant morbidities, including brain damage, seizures and epilepsy. XOMA, leveraging its scientific expertise in allosteric monoclonal antibodies, developed the XMet platform, consisting of separate classes of selective insulin receptor modulators (SIRMs) that could have a major effect on treating patients with abnormal metabolic states. X358 is a fully human negative allosteric modulating insulin receptor antibody derived from the XMet platform. It is being investigated as a novel treatment for non-drug-induced, endogenous hyperinsulinemic hypoglycemia (low blood glucose caused by excessive insulin production), as well as hypoglycemia after bariatric surgery. XOMA is conducting Phase 2 development activities for X358 in patients with congenital hyperinsulinism (CHI) and in patients with hypoglycemia post-bariatric surgery (PBS). A therapy that safely and effectively mitigates insulin-induced hypoglycemia has the potential to address a significant unmet therapeutic need for certain rare medical conditions associated with hyperinsulinism. More information on the X358 clinical trials may be found at www.clinicaltrials.gov and www.clinicaltrialsregister.eu. Open-label, Phase 2 studies established proof-of concept for X358 in 14 patients with congenital hyperinsulinism (CHI) and 13 patients with hypoglycemia post-bariatric surgery (PBS). The CHI studies were performed with expert disease centers in Philadelphia, Magdeburg, Germany, and London, and top U.S. centers in Denver, Baltimore, Boston, and Rochester, Minnesota conducted the PBS study. The Phase 2 studies were monitored for safety, and serial blood samples were collected for pharmacokinetic and pharmacodynamic assessments.  Various markers of drug activity were assessed, including changes in glucose, ketones, insulin, C-peptide and free fatty acid levels. Controlled tests included monitored fasts, protein challenges, and oral glucose tolerance. About X129
X129 is a fully human, high affinity monoclonal antibody fragment that specifically targets the human insulin receptor (INSR).  Insulin is the major hormone for lowering blood glucose levels. Profound hypoglycemia (low blood sugar) can result in significant morbidities, including organ damage and potentially death.  There are acute and more persistent hypoglycemia conditions associated with abnormally high insulin levels, which represent unmet medical needs. As a negative allosteric modulator, X129 binds with high affinity to a site distinct from insulin binding and dampens insulin signaling.  This drug candidate has been designed to provide a rapid onset of action and a duration of action tailored to meet the pharmacotherapy needs in certain conditions.  About PTH1R Monoclonal Antibodies
XOMA has developed several unique functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism.  These antibodies have shown promising efficacy in in vivo studies and could potentially address high unmet medical needs, including primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM).  About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies.  Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics.  There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.  Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: our extensive portfolio of products and technologies expected to generate substantial milestone payments and royalties over time; the future progress of the X358 or X129 clinical programs and their successful outcomes to benefit patients; our intent to maximize the value of X358 or X129 through a licensing agreement; our belief that licensing X358 of X129 will expedite patient access to X358 or X129; our portfolio of assets that address unmet medical needs, particularly in orphan indications and oncology; and our future growth potential. The words "estimate," "anticipate," "intend," "expect," "potential" and similar expressions are intended to identify forward-looking statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.
CONTACTS:

Investor contact:
Luke Heagle
Pure Communications
1 910-726-1372
[email protected]

Media contact:
Colin Sanford
Pure Communications
1 415-946-1094
[email protected]

Read more...
XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation

Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA’s balance sheet, reflecting its new business strategy

BERKELEY, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it has fully prepaid the outstanding balance of approximately $6.5 million under the Company’s term loan with Hercules Technology Growth Capital, Inc., in accordance with the terms of the loan agreement.
“This loan prepayment is another important step in our strategy to reduce debt and strengthen our balance sheet, as we continue to pursue our goal of becoming a profitable company,” said Jim Neal, Chief Executive Officer of XOMA. “We have decreased our debt by approximately $16.7 million, or 39 percent, in the past three months. We continue our focus on initiatives that enhance our financial position. Our lean cost structure gives us the opportunity to reach positive cash flow more quickly, creating value for shareholders as we realize multiple revenue streams from our portfolio of programs that are fully funded by partners across the biopharma landscape.” XOMA funded this extinguishment using, in part, proceeds of the approximately $25 million equity offering to Biotechnology Value Fund, L.P., completed in February 2017. About XOMA Corporation XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies.  Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics.  There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.  Forward-Looking Statements Certain statements contained in this press release are forward-looking statements, including our ability to reach positive cash flow and profitability and recognize revenue from our portfolio of fully funded programs, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.
Investor contact:
Luke Heagle
Pure Communications
1 910-726-1372
[email protected]

Media contact:
Colin Sanford
Pure Communications
1 415-946-1094
[email protected]

Read more...
Xoma Stock Tumbles 3.81% After Earnings Release The company was one of the top gainers last week, and investors expected it to report a rise in EPS
Xoma Corp. (NASDAQ:XOMA) stock rose 26% by the end of last week as investors eagerly awaited the company's latest earnings report. Read more...
XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Direction on March 16, 2017

BERKELEY, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it will issue its fourth quarter and full year 2016 financial results before the market opens on Thursday, March 16, 2017. In conjunction, the Company will host a conference call at 9:00 a.m. ET on Thursday, March 16, 2017, to review its business highlights and describe XOMA’s new strategic direction and initiatives. The webcast can be accessed via the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay. An accompanying slide presentation also can be accessed via the XOMA website. Telephone numbers for the live conference call are 1-877-369-6589 (U.S./Canada) and 1-408-337-0122 (international) with the passcode 82058103. About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies.  Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics.  There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.
CONTACTS:

Investor contact:
Luke Heagle
Pure Communications
1 910-726-1372
[email protected]

Media contact:
Colin Sanford
Pure Communications
1 415-946-1094
[email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 22.13
XOMA's PS Ratio is ranked higher than
60% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. XOMA: 22.13 )
Ranked among companies with meaningful PS Ratio only.
XOMA' s PS Ratio Range Over the Past 10 Years
Min: 0.55  Med: 4.16 Max: 37.28
Current: 22.13
0.55
37.28
EV-to-EBIT -1.09
XOMA's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. XOMA: -1.09 )
Ranked among companies with meaningful EV-to-EBIT only.
XOMA' s EV-to-EBIT Range Over the Past 10 Years
Min: -695.3  Med: -4.8 Max: 17.1
Current: -1.09
-695.3
17.1
EV-to-EBITDA -1.10
XOMA's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. XOMA: -1.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
XOMA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.6  Med: -4 Max: 233.3
Current: -1.1
-58.6
233.3
Current Ratio 0.97
XOMA's Current Ratio is ranked lower than
90% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. XOMA: 0.97 )
Ranked among companies with meaningful Current Ratio only.
XOMA' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 3.54 Max: 23.37
Current: 0.97
0.63
23.37
Quick Ratio 0.97
XOMA's Quick Ratio is ranked lower than
87% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. XOMA: 0.97 )
Ranked among companies with meaningful Quick Ratio only.
XOMA' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 3.45 Max: 23.37
Current: 0.97
0.63
23.37
Days Sales Outstanding 263.26
XOMA's Days Sales Outstanding is ranked higher than
77% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. XOMA: 263.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
XOMA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.48  Med: 54.2 Max: 263.26
Current: 263.26
24.48
263.26

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.10
XOMA's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. XOMA: -5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XOMA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -82.3  Med: -14.9 Max: 0
Current: -5.1
-82.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 5.34
XOMA's Price-to-Median-PS-Value is ranked lower than
81% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. XOMA: 5.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XOMA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 3.8 Max: 68.48
Current: 5.34
0
68.48
Earnings Yield (Greenblatt) % -90.31
XOMA's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. XOMA: -90.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XOMA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -94.87  Med: 8.3 Max: 19.6
Current: -90.31
-94.87
19.6

More Statistics

Revenue (TTM) (Mil) $1.86
EPS (TTM) $ -9.94
Beta2.67
Short Percentage of Float17.01%
52-Week Range $3.96 - 14.33
Shares Outstanding (Mil)7.59

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 13 5 8
EPS ($) -1.64 -0.62 -0.29
EPS without NRI ($) -1.64 -0.62 -0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference May 15 2017 
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition Apr 24 2017 
XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program Apr 18 2017 
XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Associ Mar 28 2017 
XOMA Announces Four Presentations at the 2017 ENDO Meeting Mar 23 2017 
XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation Mar 22 2017 
Xoma Stock Tumbles 3.81% After Earnings Release Mar 17 2017 
XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focuse Mar 14 2017 
Horizon Pharma plc Chairman and Chief Executive Officer Timothy P. Walbert Inducted Into Chicago Are Oct 09 2015 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Xoma Corporation of Pendency of Cl Jul 30 2015 

More From Other Websites
XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical... May 18 2017
XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference May 15 2017
Xoma reports 1Q loss May 09 2017
XOMA Reports First Quarter 2017 Financial Results May 09 2017
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA Apr 25 2017
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition Apr 24 2017
XOMA (XOMA) Shares March Higher, Can It Continue? Apr 21 2017
XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program Apr 18 2017
XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American... Mar 28 2017
Idera Pharmaceuticals and XOMA Find Paths to Financial Growth Mar 23 2017
XOMA Announces Four Presentations at the 2017 ENDO Meeting Mar 23 2017
XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation Mar 22 2017
Xoma Stock Tumbles 3.81% After Earnings Release Mar 17 2017
XOMA Reports Fourth Quarter and Full Year 2016 Financial Results Mar 16 2017
XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call... Mar 14 2017
XOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care... Feb 28 2017
Biotech Industry Poised for a Breakout in 2017? Today's Reports on Cellect Biotechnology and XOMA Feb 15 2017
Xoma Launches $25 Million Registered Offering Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)